Abemaciclib Plus Fulvestrant in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Final Overall Survival Results From MONARCH 2 ...
An evolving understanding of the risks and benefits of HRT has led to a reevaluation of the role of HRT for breast cancer survivors.
A study led by researchers at the Hospital del Mar Research Institute advances one of the most significant milestones in breast cancer treatment, making immunotherapy effective against the most common ...
Impact of Propofol Exposure on Neurocognitive Outcomes in Children With High-Risk B ALL: A Children's Oncology Group Study In AMEERA-5 (ClinicalTrials.gov identifier: NCT04478266), a double-blind, ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive results from the Phase III evERA study evaluating ...
In this segment, Dr. Gregory Vidal explains why it is essential for patients to understand their hormone receptor status and ...
HealthDay on MSN
EBCC: Active surveillance seems safe for grade 1 to 2 DCIS
Active surveillance seems safe for women with estrogen receptor-positive, human epidermal growth factor receptor 2 ...
For women age 70 and over with a common form of breast cancer, determining "the right size" of treatment can be challenging, ...
Health and Me on MSN
Amanda Peet opens up about breast cancer battle, shares toughest moment
Amanda Peet was diagnosed with stage 1 of lobular cancer that is “hormone-receptor-positive” and “HER2-negative”. The 54-year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results